Q-omics provides the consensus-scored PHBP18 profile across patient tissues and cancer cell-line models. PHBP18 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, PHBP18 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, PHBP18 RNA expression shows 6,745 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, COAD, and STAD as cancer lineages where PHBP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP18 survival associations across molecular data types. PHBP18 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP18 RNA expression–survival associations across cancer types. High PHBP18 expression shows unfavorable associations in THYM, BRCA, MESO, DLBC and PCPG, but favorable associations in BLCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify THYM as the clearest survival context for PHBP18 RNA expression.
This table summarizes PHBP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP18 shows lower tumor expression in KICH and KIRP and higher tumor expression in COAD and LUSC. The COAD box plot shows higher PHBP18 RNA expression in tumor versus normal tissue (log2 FC = +0.251, t-test p < 0.001).
This table shows molecular features associated with PHBP18 in patient tissues and cancer cell lines. In patient samples, PHBP18 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
